



## Clinical trial results:

### A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Spain (CANTABRICO).

#### Summary

EudraCT number	2020-002328-35
Trial protocol	ES
Global end of trial date	21 June 2023

#### Results information

Result version number	v1
This version publication date	05 July 2024
First version publication date	05 July 2024

#### Trial information

##### Trial identification

Sponsor protocol code	D419QC00005
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04712903
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	Puerto de Somport 21-23, Madrid, Spain, 28050
Public contact	Global Clinical Lead, AstraZeneca, +1 877-240-9479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 September 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 June 2023
Global end of trial reached?	Yes
Global end of trial date	21 June 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To describe safety profile of durvalumab in combination with platinum-etoposide as first-line treatment for patients with ES-SCLC

Protection of trial subjects:

The patient signed the informed consent before carrying out any procedure related to the study. Physical examination, hematology, biochemistry, ECG and evaluation of the tumor were made before the inclusion of the patient in the study and during the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 December 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 101
Worldwide total number of subjects	101
EEA total number of subjects	101

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	44
From 65 to 84 years	57
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Of the 126 patients included in the study, 25 were screening failures and 101 patients have been analysed. All patients included in the analysis started treatment with chemotherapy and durvalumab and 81 of them started maintenance treatment with durvalumab.

### Pre-assignment

Screening details:

All patients that met selection criteria and signed the informed consent form were included in the study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Experimental arm
------------------	------------------

Arm description:

Received study intervention

Arm type	Experimental
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.

<b>Number of subjects in period 1</b>	Experimental arm
Started	101
Completed	101

## Baseline characteristics

### Reporting groups

Reporting group title	Experimental arm
-----------------------	------------------

Reporting group description:
------------------------------

Received study intervention
-----------------------------

Reporting group values	Experimental arm	Total	
Number of subjects	101	101	
Age Categorical			
Units: Participants			
<=18 years	0	0	
Between 18 and 65 years	44	44	
>=65 years	57	57	
Age Continuous			
Units: Years			
arithmetic mean	66.2		
standard deviation	± 7.2	-	
Sex: Female, Male			
Units:			
Female	33	33	
Male	68	68	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	21	21	
Not Hispanic or Latino	80	80	
Unknown or Not Reported	0	0	
Smoking status			
Units: Subjects			
Current smoker	46	46	
Former smoker	53	53	
Not available	2	2	
Weight			
Units: Kg			
arithmetic mean	75.6		
standard deviation	± 16.8	-	

## End points

### End points reporting groups

Reporting group title	Experimental arm
Reporting group description:	
Received study intervention	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	
Subject analysis set title	Completed
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Completed the items in the questionnaire.	

### Primary: Incidence of adverse events (AEs) grade $\geq 3$

End point title	Incidence of adverse events (AEs) grade $\geq 3$ <sup>[1]</sup>
End point description:	
Patients with AEs grade $\geq 3$ according to NCI CTCAE v5.0	
End point type	Primary
End point timeframe:	
During study treatment	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Single arm, descriptive.

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Participants				
Yes	77			
No	24			

## Statistical analyses

No statistical analyses for this end point

### Primary: Incidence of immune-mediated adverse events (imAE)

End point title	Incidence of immune-mediated adverse events (imAE) <sup>[2]</sup>
-----------------	---

End point description:

Patients with immune-mediated adverse events (imAE) per patient

End point type	Primary
----------------	---------

End point timeframe:

During study treatment

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Single arm, descriptive.

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Participants				
Yes	38			
No	63			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Response (DoR)

End point title	Duration of Response (DoR)
-----------------	----------------------------

End point description:

DoR: Defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

End point type	Secondary
----------------	-----------

End point timeframe:

At least every 12 weeks

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: Months				
median (confidence interval 95%)	5.6 (4.7 to 6.5)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
OS: Defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.	
End point type	Secondary
End point timeframe:	
Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Months				
median (confidence interval 95%)	9.6 (7.8 to 11.3)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression Free Survival (PFS).

End point title	Progression Free Survival (PFS).
End point description:	
PFS: Defined as the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from investigational product or receives another anticancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable assessment.	
End point type	Secondary
End point timeframe:	
At least every 12 weeks	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Months				
median (confidence interval 95%)	6.1 (5.2 to 6.9)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
End point description: Patients who achieve a complete or partial response during study treatment.	
End point type	Secondary
End point timeframe: At least every 12 weeks	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	54.5 (44.7 to 64.2)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Treatment Discontinuation (TTD)

End point title	Time to Treatment Discontinuation (TTD)
End point description: TTD: Defined as the time from the first date of treatment until the end of treatment date.	
End point type	Secondary
End point timeframe: From start of treatment until end of treatment.	



End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Months				
median (inter-quartile range (Q1-Q3))	6.2 (4.5 to 9.9)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS rate at 12 months

End point title	OS rate at 12 months
End point description: Proportion of participants remaining alive at 12 months after initiation of study treatment.	
End point type	Secondary
End point timeframe: Every 12 weeks	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	40.7 (31.1 to 50.3)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS rate at 18 months

End point title	OS rate at 18 months
End point description: Proportion of participants remaining alive at 18 months after initiation of study treatment.	
End point type	Secondary
End point timeframe: Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	31.6 (22.4 to 40.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: PFS rate at 6 months

End point title	PFS rate at 6 months
End point description: Proportion of participants remaining alive without disease progression at 6 months after initiation of study treatment.	
End point type	Secondary
End point timeframe: Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	53.0 (43.2 to 62.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: PFS rate at 12 months

End point title	PFS rate at 12 months
End point description: Proportion of participants remaining alive without disease progression at 12 months after initiation of study treatment.	
End point type	Secondary
End point timeframe: Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	21.0 (13.0 to 29.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: DoR rate at 12 months

End point title	DoR rate at 12 months
End point description: Proportion of responders remaining alive without disease progression at 12 months after first response.	
End point type	Secondary
End point timeframe: Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: Percentage				
number (confidence interval 95%)	35.7 (23.0 to 48.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS rate at 6 months

End point title	OS rate at 6 months
End point description: Proportion of participants remaining alive at 6 months after initiation of study treatment.	
End point type	Secondary
End point timeframe: Every 12 weeks	

<b>End point values</b>	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage				
number (confidence interval 95%)	75.2 (66.8 to 83.6)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Global Health Status, change from baseline

End point title	QLQ-C30: Global Health Status, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

<b>End point values</b>	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	67			
Units: Units				
arithmetic mean (standard deviation)	-6.3 ( $\pm$ 30.8)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Role Functioning, change from baseline

End point title	QLQ-C30: Role Functioning, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

<b>End point values</b>	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-17.0 ( $\pm$ 36.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Physical Functioning, change from baseline

End point title	QLQ-C30: Physical Functioning, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

<b>End point values</b>	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-15.0 ( $\pm$ 29.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Emotional Functioning, change from baseline

End point title	QLQ-C30: Emotional Functioning, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-2.3 ( $\pm$ 30.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Cognitive Functioning, change from baseline

End point title	QLQ-C30: Cognitive Functioning, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-15.0 ( $\pm$ 24.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Insomnia, change from baseline

End point title	QLQ-C30: Insomnia, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	68			
Units: Units				
arithmetic mean (standard deviation)	1.0 ( $\pm$ 36.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Dyspnea, change from baseline

End point title	QLQ-C30: Dyspnea, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-2.4 ( $\pm$ 37.2)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Nausea, change from baseline

End point title	QLQ-C30: Nausea, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	0.7 ( $\pm$ 20.1)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Pain, change from baseline

End point title	QLQ-C30: Pain, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	0.2 ( $\pm$ 29.2)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Social Functioning, change from baseline

End point title	QLQ-C30: Social Functioning, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	



End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	67			
Units: Units				
arithmetic mean (standard deviation)	-12.0 ( $\pm$ 31.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Fatigue, change from baseline

End point title	QLQ-C30: Fatigue, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	12.4 ( $\pm$ 29.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Cough, change from baseline

End point title	QLQ-LC13: Cough, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	73			
Units: Units				
arithmetic mean (standard deviation)	-7.8 (± 29.7)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Diarrhea, change from baseline

End point title	QLQ-C30: Diarrhea, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	0.0 (± 18.1)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Financial difficulties, change from baseline

End point title	QLQ-C30: Financial difficulties, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	65			
Units: Units				
arithmetic mean (standard deviation)	10.3 ( $\pm$ 22.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Constipation, change from baseline

End point title	QLQ-C30: Constipation, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	6.3 ( $\pm$ 33.5)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-C30: Anorexia, change from baseline

End point title	QLQ-C30: Anorexia, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	69			
Units: Units				
arithmetic mean (standard deviation)	-2.4 (± 36.3)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Haemoptysis, change from baseline

End point title	QLQ-LC13: Haemoptysis, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	73			
Units: Units				
arithmetic mean (standard deviation)	-0.5 (± 15.2)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Pain in arm, change from baseline

End point title	QLQ-LC13: Pain in arm, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	71			
Units: Units				
arithmetic mean (standard deviation)	3.3 ( $\pm$ 33.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Sore mouth

End point title	QLQ-LC13: Sore mouth
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	71			
Units: Units				
arithmetic mean (standard deviation)	2.3 ( $\pm$ 13.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Other Pain, change from baseline

End point title	QLQ-LC13: Other Pain, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	68			
Units: Units				
arithmetic mean (standard deviation)	7.4 ( $\pm$ 39.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Dyspnea, change from baseline

End point title	QLQ-LC13: Dyspnea, change from baseline
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks during chemotherapy treatment and every 4 weeks during maintenance treatment.	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	68			
Units: Units				
arithmetic mean (standard deviation)	3.1 ( $\pm$ 24.1)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Chest pain

End point title	QLQ-LC13: Chest pain
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	73			
Units: Units				
arithmetic mean (standard error)	-1.8 ( $\pm$ 29.3)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Dysphagia

End point title	QLQ-LC13: Dysphagia
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	72			
Units: Units				
arithmetic mean (standard error)	2.8 ( $\pm$ 23.6)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Alopecia

End point title	QLQ-LC13: Alopecia
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	72			
Units: Units				
arithmetic mean (standard deviation)	18.1 ( $\pm$ 37.5)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: QLQ-LC13: Neuropathy

End point title	QLQ-LC13: Neuropathy
End point description:	
Final score minus baseline score	
End point type	Secondary
End point timeframe:	
Every 3 weeks	

End point values	Completed			
Subject group type	Subject analysis set			
Number of subjects analysed	71			
Units: Units				
arithmetic mean (standard deviation)	13.6 ( $\pm$ 27.4)			

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

18 months

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	Experimental arm
-----------------------	------------------

Reporting group description:

Received study intervention

Serious adverse events	Experimental arm		
Total subjects affected by serious adverse events			
subjects affected / exposed	57 / 101 (56.44%)		
number of deaths (all causes)	76		
number of deaths resulting from adverse events	8		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder neoplasm			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal neoplasm			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Superior vena cava syndrome			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	4 / 101 (3.96%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Obstructive airways disorder			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusional state			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Neutrophil count decreased			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Transaminases increased			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Radial head dislocation			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac failure			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial flutter			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebellar syndrome			

subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Dizziness				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemorrhage intracranial				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Immune-mediated neurological disorder				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	1 / 1			
Multiple sclerosis				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Neurological decompensation				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Seizure				
subjects affected / exposed	2 / 101 (1.98%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Spinal cord compression				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Syncope				

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Pancytopenia			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences causally related to treatment / all	7 / 10		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Diplopia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bile duct stone			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Skin reaction			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nephritis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal tubular disorder			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Bone pain			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Staphylococcal infection			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	4 / 101 (3.96%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 2		
Respiratory tract infection			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonia			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	1 / 1		
Herpes zoster reactivation			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19 pneumonia			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
COVID-19			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Experimental arm		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	100 / 101 (99.01%)		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	15 / 101 (14.85%)		
occurrences (all)	17		
Asthenia			
subjects affected / exposed	64 / 101 (63.37%)		
occurrences (all)	157		
Mucosal inflammation			
subjects affected / exposed	10 / 101 (9.90%)		
occurrences (all)	12		
Oedema peripheral			



subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	13		
Illness			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences (all)	8		
Fatigue			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences (all)	10		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	23 / 101 (22.77%)		
occurrences (all)	28		
Dyspnoea			
subjects affected / exposed	31 / 101 (30.69%)		
occurrences (all)	40		
Haemoptysis			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	7		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	8		
Investigations			
Platelet count decreased			
subjects affected / exposed	11 / 101 (10.89%)		
occurrences (all)	15		
Neutrophil count decreased			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	15		
Alanine aminotransferase increased			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	10		
Amylase increased			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	16		
Lymphocyte count decreased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Gamma-glutamyltransferase increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Aspartate aminotransferase increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 101 (4.95%)</p> <p>13</p> <p>5 / 101 (4.95%)</p> <p>11</p> <p>6 / 101 (5.94%)</p> <p>9</p>		
<p>Nervous system disorders</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dysgeusia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 101 (7.92%)</p> <p>8</p> <p>5 / 101 (4.95%)</p> <p>6</p> <p>5 / 101 (4.95%)</p> <p>6</p>		
<p>Blood and lymphatic system disorders</p> <p>Neutropenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thrombocytopenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>34 / 101 (33.66%)</p> <p>56</p> <p>50 / 101 (49.50%)</p> <p>125</p> <p>19 / 101 (18.81%)</p> <p>27</p>		
<p>Gastrointestinal disorders</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p>	<p>21 / 101 (20.79%)</p> <p>25</p> <p>27 / 101 (26.73%)</p> <p>35</p>		

subjects affected / exposed	18 / 101 (17.82%)		
occurrences (all)	22		
Vomiting			
subjects affected / exposed	12 / 101 (11.88%)		
occurrences (all)	14		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	24 / 101 (23.76%)		
occurrences (all)	31		
Pruritus			
subjects affected / exposed	12 / 101 (11.88%)		
occurrences (all)	13		
Rash			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	11		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences (all)	6		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	15 / 101 (14.85%)		
occurrences (all)	19		
Hyperthyroidism			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	8		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	16 / 101 (15.84%)		
occurrences (all)	19		
Arthralgia			
subjects affected / exposed	14 / 101 (13.86%)		
occurrences (all)	23		
Pain in extremity			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	7		

<p>Infections and infestations</p> <p>Urinary tract infection</p> <p>subjects affected / exposed</p> <p>9 / 101 (8.91%)</p> <p>occurrences (all)</p> <p>11</p> <p>Respiratory tract infection</p> <p>subjects affected / exposed</p> <p>10 / 101 (9.90%)</p> <p>occurrences (all)</p> <p>12</p> <p>COVID-19</p> <p>subjects affected / exposed</p> <p>5 / 101 (4.95%)</p> <p>occurrences (all)</p> <p>5</p>			
<p>Metabolism and nutrition disorders</p> <p>Decreased appetite</p> <p>subjects affected / exposed</p> <p>18 / 101 (17.82%)</p> <p>occurrences (all)</p> <p>19</p> <p>Hypomagnesaemia</p> <p>subjects affected / exposed</p> <p>10 / 101 (9.90%)</p> <p>occurrences (all)</p> <p>12</p> <p>Hyperglycaemia</p> <p>subjects affected / exposed</p> <p>9 / 101 (8.91%)</p> <p>occurrences (all)</p> <p>13</p> <p>Hyponatraemia</p> <p>subjects affected / exposed</p> <p>9 / 101 (8.91%)</p> <p>occurrences (all)</p> <p>16</p>			

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 February 2021	Addition of two biomarker substudies. Additional blood sampling at baseline and every 2 cycles until cycle 8 and a fresh tumor biopsy at disease progression. Updated inclusion criterion 4B in order to allow participation in the study of patients with brain metastases treated with steroids and anticonvulsants.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported